Loading organizations...
§ Private Profile · 1800 Tysons Blvd Ste 900, McLean, Virginia, 22102, United States
TARA Mind is a technology company.
TARA Mind delivers evidence-based mental health care for high-risk employees, improving outcomes and reducing employer costs. The company establishes a premium network of vetted clinicians and therapists nationwide. This network provides access to specialized treatments, including Ketamine-Assisted Therapy, for individuals needing advanced support.
Marcus Capone founded TARA Mind, serving as its Chief Executive Officer. The company emerged from the insight into the critical demand for expanded access to safe, effective mental healthcare for at-risk employees. This understanding drove TARA Mind's creation, empowering employers to proactively address their workforce's mental well-being.
Leading employers utilize TARA Mind's services to offer comprehensive mental health support for high-risk employees. The company's vision centers on broadening access to effective, affordable care. By partnering with organizations, TARA Mind ensures individuals receive specialized therapies and support for improved well-being.
TARA Mind has raised $11.0M across 2 funding rounds.
TARA Mind has raised $11.0M in total across 2 funding rounds.
TARA Mind has raised $11.0M in total across 2 funding rounds.
TARA Mind's investors include Satori Capital, Alumni Ventures, Blake Mycoskie, Crumpton Ventures, Echo Investment Capital, Empath Ventures, Grant L. Verstandig.
TARA Mind has raised $11.0M across 2 funding rounds. Most recently, it raised $8.0M Seed in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2024 | $8M Seed | Satori Capital | Alumni Ventures, Blake Mycoskie, Crumpton Ventures, Echo Investment Capital, Empath Ventures | Announced |
| Apr 13, 2023 | $3M Pre Seed | Grant L. Verstandig | — | Announced |
TARA Mind is a mental health technology company founded in 2022 as a public benefit corporation, providing safe, affordable access to evidence-based psychedelic-assisted therapies, primarily ketamine-assisted therapy (KAT), for treatment-resistant mental health conditions like depression.[1][2][3][4] It builds a clinician-guided platform that connects employees with a national network of vetted therapists, physicians, and clinics, serving employers who subsidize these benefits to improve workforce mental health, reduce healthcare costs, and boost productivity.[1][2][3] Targeting the treatment-resistant depression (TRD) market—where 9% of U.S. adults have major depressive disorder (MDD) and one-third are treatment-resistant, costing over $29 billion annually—TARA Mind has raised $11M in seed funding, with its latest $8M round about a year ago, and reports measurable symptom reductions in under 30 days.[1][2][5]
The platform's core elements include the proprietary PTIM™ protocol (Preparation, Treatment, Integration, Monitoring), a growing Synapse CNS dataset for machine learning-driven personalized recommendations, and tools like a Mental Health Savings Calculator for employers.[1][3][4][5]
TARA Mind emerged from co-founder and CEO Marcus Capone's personal mission to address mental health crises, starting with U.S. veterans.[1][2] In 2019, Capone launched VETS® (Veterans Exploring Treatment Solutions), a 501(c)(3) nonprofit providing healing grants for psychedelic-assisted therapy to combat veteran suicide.[2] In 2021, Capone partnered with Grant Verstandig, founder of Rally Health and former Chief Digital Officer at UnitedHealth, incubating TARA Mind in 2022 under Verstandig’s Red Cell Partners, which focuses on healthcare and national security tech.[1]
The idea crystallized amid a surging mental health crisis—46 million Americans battled addiction in 2021, double from 2019—exposing flaws in accessibility, cost, and efficacy of traditional care.[4] Pivotal early traction included employer partnerships for subsidized benefits and recognitions like winning the 2024 Employer Health Innovation Roundtable (EHIR) Pitch Competition.[5]
TARA Mind stands out in mental health by pioneering a tech-enabled platform for psychedelic-assisted therapy as an employer benefit, distinct from drug developers or generic apps.[1][2][4]
TARA Mind rides the psychedelic-assisted therapy wave amid FDA breakthroughs like esketamine for TRD and growing acceptance of KAT, fueled by post-pandemic mental health surges and employer demands for effective benefits.[1][2][4] Timing aligns with market forces: TRD's $29B+ annual cost to payers/employers, 33% MDD failure rate on traditional treatments, and health equity gaps in access.[1][3]
It influences the ecosystem by creating a new category—tech platforms subsidizing advanced therapies via employers—bypassing lengthy drug development while building proprietary data moats for AI personalization.[1][2] This shifts corporate wellness from apps to precision care, partnering with leading employers to normalize PAT, reduce $193B TRD burden, and set standards for clinician-tech integration in behavioral health.[3][5]
TARA Mind is poised to scale its employer benefit model, leveraging $11M funding to expand the provider network, enhance Synapse CNS AI, and launch tools like clinical trial simulations.[1][2][5] Trends like AI in healthcare, psychedelic deregulation, and workforce mental health mandates will accelerate growth, potentially capturing more of the TRD TAM as data proves ROI.[1][3]
Influence may evolve toward broader PAT adoption, influencing policy and payers while solidifying its edge in precision mental wellness—transforming Capone's veteran-focused origins into a workforce revolution.[1][2][4]